A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Discoid Lupus Erythematosus, sponsored by LEO Pharma. Terminated at 19 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Lupus Erythematosus, Discoid with a site in Germany — 3 open to participants now, 7 under way, 5 of them phase 3. Lupus Erythematosus, Discoid · Germany.
Among the 13 studies in Lupus Erythematosus, Discoid with a site in Germany, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 4th registered.
42 studies on the registry are indexed under Lupus Erythematosus, Discoid; 7 are open to participants now.
Browse Lupus Erythematosus, Discoid studies →3 of the 13 studies in Lupus Erythematosus, Discoid with a site in Germany are open now. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in Germany, United States, Australia and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in Germany, United States, Australia and 17 more countries
Ages 18–75
Biogen · Sites in Germany, United States, Argentina and 22 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 5 Lupus Erythematosus, Discoid studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5
First in 2003; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 45 across 33 interventional studies indexed under Lupus Erythematosus, Discoid.
Median enrollment 73 across the 12 interventional studies, 77 across the 1 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
LEO Pharma has 1 study filed under Lupus Erythematosus, Discoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Lupus Erythematosus, Discoid with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE).
Main Inclusion Criteria:
Main Exclusion Criteria:
Treatment with the following medications:
Treatment with any marketed biological therapy or biologic agents:
Clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, could compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial. Clinically significant infections are defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Delgocitinib cream applied twice daily for 6 weeks
Drug: Delgocitinib cream
Delgocitinib cream vehicle applied twice daily for 6 weeks
Drug: Delgocitinib cream vehicle
Cream for topical application.
Also known as: LEO 124249 cream
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Also known as: LEO 124249 cream vehicle
Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6.
The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.
Time frame: Week 6
Number of Adverse Events (AEs) up to Week 6.
Number of AEs from baseline to Week 6
Time frame: Week 0 to Week 6
Number of Subjects With AEs up to Week 6.
Number of subjects with AEs from baseline to Week 6
Time frame: Week 0 to Week 6
Number of Lesion-specific, Treatment-related AEs up to Week 6.
The number of lesion-specific, treatment-related AEs per target lesion will be compared for active and vehicle treatment. Lesion-specific AEs are defined as lesional/perilesional AEs (i.e. AE location within the treatment area and/or ≤2 cm from the border of a target lesion).
Time frame: Week 0 to Week 6
Number of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline.
The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.
Time frame: Week 0 to Week 6
Number of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline.
The erythema score is lesion-specific and based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.
Time frame: Week 0 to Week 6
Erythema Score at Week 6.
The erythema score is lesion-specific and based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.
Time frame: Week 6
Total Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6.
The skin disease activity scores are based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The total skin disease activity score is defined as the sum of the scores for 3 clinical signs (erythema, scaling/hyperkeratosis, oedema/infiltration) for each target lesion. For the total score and the individual clinical signs, higher scores indicate more severe symptoms. Erythema is scored on a 4-point scale ranging from 0 (absent) to 3 (dark red, purple/violaceous/crusted/haemorrhagic). Hyperkeratosis/scaling is scored on a 3-point scale from 0 (absent) to 2 (verrucous hyperkeratosis). Oedema/infiltration is scored on a 3-point scale from 0 (absent) to 2 (palpable and visible). The total skin disease activity score can therefore range from 0 to 7.
Time frame: Week 6
37 subjects screened. 27 subjects randomised. 26 subjects completed.
| Milestone | All Subjects |
|---|---|
| Started | 27 |
| Lesions treated with delgocitinib cream | 27 |
| Lesions treated with delgocitinib cream vehicle | 27 |
| Completed | 26 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.
| lesions | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|
| Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6. | 3 | 6 |
Number of AEs from baseline to Week 6
| AEs | All Subjects |
|---|---|
| Number of Adverse Events (AEs) up to Week 6. | 8 |
Number of subjects with AEs from baseline to Week 6
| Participants | All Subjects |
|---|---|
| Number of Subjects With AEs up to Week 6. | 8 |
The number of lesion-specific, treatment-related AEs per target lesion will be compared for active and vehicle treatment. Lesion-specific AEs are defined as lesional/perilesional AEs (i.e. AE location within the treatment area and/or ≤2 cm from the border of a target lesion).
| AEs | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|
| Number of Lesion-specific, Treatment-related AEs up to Week 6. | 2 | 0 |
The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.
| lesions | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|
| Number of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline. | 3 | 6 |
The erythema score is lesion-specific and based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.
| lesions | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|
| Number of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline. | 5 | 5 |
The erythema score is lesion-specific and based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.
| scores on a scale | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|
| Erythema Score at Week 6. | 1.5 (1 to 2) | 1.5 (1 to 2) |
The skin disease activity scores are based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The total skin disease activity score is defined as the sum of the scores for 3 clinical signs (erythema, scaling/hyperkeratosis, oedema/infiltration) for each target lesion. For the total score and the individual clinical signs, higher scores indicate more severe symptoms. Erythema is scored on a 4-point scale ranging from 0 (absent) to 3 (dark red, purple/violaceous/crusted/haemorrhagic). Hyperkeratosis/scaling is scored on a 3-point scale from 0 (absent) to 2 (verrucous hyperkeratosis). Oedema/infiltration is scored on a 3-point scale from 0 (absent) to 2 (palpable and visible). The total skin disease activity score can therefore range from 0 to 7.
| scores on a scale | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|
| Total Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6. | 2.5 (2 to 4) | 2.5 (1 to 4) |
Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | 0/27 (0%) | 0/27 (0%) | 10/27 (37%) |
| Event | All Subjects |
|---|---|
| NasopharyngitisInfections and infestations | 4/27 |
| Cutaneous lupus erythematosusSkin and subcutaneous tissue disorders | 1/27 |
| Rash erythematousSkin and subcutaneous tissue disorders | 1/27 |
| Middle ear inflammationEar and labyrinth disorders | 1/27 |
| Gastrointestinal disorderGastrointestinal disorders | 1/27 |
| Application site painGeneral disorders | 1/27 |
| Application site pruritusGeneral disorders | 1/27 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/27 |
| HeadacheNervous system disorders | 1/27 |
Randomised subjects
| Age, Continuous(years) | All Randomised Subjects |
|---|---|
| Mean | 45.7 ± 13.4 |
| Sex: Female, Male(Participants) | All Randomised Subjects |
|---|---|
| Female | 15 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | All Randomised Subjects |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | All Randomised Subjects |
|---|---|
| Race — Black or African American | 2 |
| Race — White | 20 |
| Race — Other | 4 |
| Race — Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | All Randomised Subjects |
|---|---|
| United States | 4 |
| Denmark | 1 |
| France | 5 |
| Germany | 17 |
| Investigator's Global Assessment (IGA) of lesions to be treated with delgocitinib cream(percentage of lesions) | All Randomised Subjects |
|---|---|
| IGA score 3 (moderate) | 88.9 |
| IGA score 4 (severe) | 11.1 |
| Investigator's Global Assessment (IGA) of lesions to be treated with vehicle(percentage of lesions) | All Randomised Subjects |
|---|---|
| IGA score 3 (moderate) | 88.9 |
| IGA score 4 (severe) | 11.1 |
| Baseline erythema score of lesions to be treated with delgocitinib cream(percentage of lesions) | All Randomised Subjects |
|---|---|
| Erythema score 2 | 37.0 |
| Erythema score 3 | 63.0 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Apr 2020, 9 months.
Results were first posted in Jun 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib
Lupus Erythematosus, Discoid →